SCARSDALE, N.Y., May 20, 2025 /PRNewswire/ -- Maipl Therapeutics, Inc. ("Maipl"), a biopharmaceutical company focused on first‑in‑class, non‑hormonal therapies for women's health, today announced a strategic alliance with Endosure, Inc., the developer of the ENDOSURE TEST—the only Tier-1 non‑invasive, 30-minute and highly accurate diagnostic with rapid results capable of diagnosing or excluding the presence of endometriosis in any anatomical location. The collaboration will leverage the ENDOSURE TEST to expedite Maipl's clinical studies of MA-4604, a potent and selective antagonist of the Prostaglandin‑F2α receptor (FP), with the goals of accelerating patient identification, enrollment and pharmacodynamic assessment.

Click to Read the Full Press Release >>